Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Regulated Protein Degradation02:58

Regulated Protein Degradation

2.5K
2.5K
The Proteasome02:18

The Proteasome

8.5K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
8.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

6.0K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.0K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Study on the Effect and Mechanism of the Outer Membrane Vesicles of <i>Porphyromonas gingivalis</i> on the Function and Extracellular Matrix of Mouse Aortic Smooth Muscle Cells.

Microorganisms·2026
Same author

Efavirenz Mitigates Dyslipidemia and Attenuates Ulcerative Colitis through Gut Microbiota Modulation.

ACS infectious diseases·2026
Same author

Prognostic significance of PCR-based measurable residual disease post-induction and during consolidation in pediatric KMT2A-rearranged acute myeloid leukemia.

Leukemia research·2026
Same author

Quality and reliability of vascular cognitive impairment-related information on Chinese social media platforms.

Medicine·2026
Same author

Diosgenin alleviates hepatic fibrosis via PI3K/Akt/mTOR mediated fatty acid metabolic reprogramming and NF-κB activation.

Journal of ethnopharmacology·2026
Same author

Alternative mRNA splicing events and regulators in epidermal differentiation.

Cell reports·2026

相关实验视频

Updated: Jun 4, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.4K

最近在开发向蛋白质降解剂方面取得的进展.

Binbin Cheng1, Hongqiao Li2, Xiaopeng Peng3

  • 1Hubei Key Laboratory for Kidney Disease Pathogenesis and Intervention, Hubei Polytechnic University, Huangshi, 435003, China; Central Laboratory, Wenzhou Medical University Lishui Hospital, Lishui People's Hospital, Lishui, Zhejiang, 323000, China.

European journal of medicinal chemistry
|December 30, 2024
PubMed
概括

向蛋白质降解 (TPD) 使用小分子来消除引起疾病的蛋白质. 本综述探讨了TPD连接体,它们的机制,如蛋白酶体或溶酶体向,以及未来的潜力.

关键词:
这就是HyTTD.这就是LYTACs.分子粘合剂是分子粘合剂.这就是 PROTACs.小分子连接体是小分子连接体.有针对性的蛋白质降解降解.

更多相关视频

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.2K

相关实验视频

Last Updated: Jun 4, 2025

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

9.4K
Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.1K
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.2K

科学领域:

  • 生物化学和药物化学 医学化学
  • 药物发现和开发 药物发现和开发
  • 分子生物学分子生物学

背景情况:

  • 向蛋白质降解 (TPD) 是一种新兴的治疗策略,利用创新模式.
  • 关键的TPD策略包括蛋白质溶解向嵌合体 (PROTACs),分子,疏水性标签结合降解剂 (HyTTD) 和溶酶体向嵌合体 (LYTACs).
  • 小分子连接体是指导向蛋白质降解的关键组成部分.

研究的目的:

  • 提供TPD中使用的小分子配体的全面概述.
  • 讨论各种TPD配体的设计原理,优势和局限性.
  • 探索TPD技术的未来前景和发展轨迹.

主要方法:

  • 文献综述和对TPD小分子连接体的当前研究的综合.
  • 通过蛋白酶体,溶酶体,自和疏水标记系统调解的降解途径的分析.
  • 讨论设计策略和对TPD方法的比较评估.

主要成果:

  • 小分子配体是TPD的核心,使得有针对性的蛋白质消除.
  • 干可以利用细胞机械,如蛋白质体和 lysosome 降解.
  • 不同的TPD策略 (PROTAC,分子等) 它们提供了独特的优势,并面临着特定的挑战.

结论:

  • 小分子连接体是推动TPD疗法的进步的多功能工具.
  • 了解连接体设计和降解途径是优化TPD疗效的关键.
  • 对于未来的药物开发和治疗策略,TPD技术具有显著的前景.